Search

Two-year GATHER2 data: anatomical gains, functional questions for avacincaptad pegol in geographic atrophy

Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) remains a leading cause of irreversible central vision loss, and complement dysregulation has long been implicated in its pathogenesis. In 2023, the US FDA approved the first two GA therapies, both...

Elevated anxiety levels in central serous chorioretinopathy

This prospective cross-sectional case-control, questionnaire-based study was aimed to compare association of anxiety disorder in patients with central serous chorioretinopathy (CSCR) and age-gender-matched healthy controls. Participants in the age group of 18–55 years were divided into 2 groups. Group A...

Combined phacoemulsification and hydrus microstent for normal tension glaucoma

This retrospective multicentre study followed up 77 normal tension glaucoma (NTG) eyes undergoing phacoemulsification and Hydrus implantation between 2014 and 2023 over a 36-month period. Primary outcomes were changes in intraocular pressure (IOP) and medication burden, and cumulative success probabilities...